Moxetumomab Pasudotox Has Activity in Relapsed/Refractory Hairy Cell Leukemia

Share this content:

(ChemotherapyAdvisor) – The anti-CD22 recombinant immunotoxin moxetumomab pasudotox has shown activity in patients with chemotherapy-resistant hairy cell leukemia (HCL) and has a safety profile supporting further clinical development, results of a Phase 1 study published in the Journal of Clinical Oncology online February 21, 2012, have shown.

The dose-escalating study enrolled 28 patients, three each at 5, 10, 20, and 30µg/kg, four patients at 40µg/kg, and 12 patients at 50µg/kg three times daily for 1–16 cycles each (median, 4 cycles). No dose-limiting toxicities were observed; two patients had transient laboratory abnormalities consistent with grade 2 hemolytic uremic syndrome. The grade 1/2 toxicities that occurred in 25% to 64% of patients were, in decreasing frequency, “hypoalbuminemia, aminotransferase elevations, edema, headache, hypotension, nausea, and fatigue,” the investigators noted.

Ten of the twenty-six patients (38%) evaluable for immunogenicity produced antibodies that neutralized >75% of the cytotoxicity of 1,000ng/mL of immunotoxin; however, this immunogenicity was rare (5%) after cycle 1, they noted.

Responses were observed at all dose levels. Overall response rate was 86%. Complete remission (CR) was observed in 13 patients (46%). These CRs were durable and without evidence of minimal residual disease; only one lasted <1 year. “CRs were achieved only in patients without prior splenectomy,” they wrote. Median disease-free survival was not reached at 26 months.

“We believe these Phase I results support a pivotal trial in which patients with multiply relapsed HCL are randomly assigned between moxetumomab pasudotox and best alternative therapy (ie, rituximab or cladribine),” they noted. To further delineate efficacy and safety, patients with HCL are continuing to receive the 50µg/kg three times daily dosage. In addition, clinical trials are exploring the use of moxetumomab pasudotox for chronic lymphocytic leukemia and non-Hodgkin's lymphoma in adults and acute lymphoblastic leukemia in children.



Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs